





UTILIDAD CLÍNICA DE LA CAPILAROSCOPIA

Dr. V. Fonollosa Pla
Dra. CP. Simeón Aznar
Dr. M. Vilardell Tarrés



CAPILAROSCOPIA

Microcirculación cutánea
Porción venular
Porción arteriolar



Morfología capilar
Lecho periungueal

CAPILAROSCOPIA. Limitaciones

Baja especificidad

Falta de criterios de normalidad

Falta de terminología uniforme

Dificultad para incorporar análisis cuantitativos

Dependencia de la experiencia e interpretación del observador



CAPILAROSCOPIA. Semiología



Sinuoides




Ramificaciones



Dilataciones




Pérdida capilar



Hemorragias

Scoring the nailfold microvascular changes during the capillaroscopic analysis in systemic sclerosis patients



Predictive role of capillaroscopic skin ulcer risk index in systemic sclerosis: a multicentre validation study





Figure 2 Algorithm for capillaroscopic skin ulcer risk index (CSURI) evaluation. D, Maximum diameter of megacapillary; M, number of megacapillaries (diameter $\geq 50 \mu\text{m}$); N, number of capillaries.

Predictive role of capillaroscopic skin ulcer risk index in systemic sclerosis: a multicentre validation study



Sebastiani M et al. Ann Rheum Dis. 2011

CAPILAROSCOPIA y ENFERMEDAD

Diagnóstico - Pronóstico

Acrosíndromes vasculares

Conectivopatías

Arteriopatías

Enfermedades cutáneas

Enfermedades hematológicas

Enfermedades neuropsiquiátricas

CAPILAROSCOPIA. Acrosíndromes

Acrocianosis

Livedo reticularis

Fenómeno de Raynaud

Eritromelalgia

ACROCIANOSIS



Estasis vascular



Maurice Raynaud

Fenómeno de Raynaud



F.Raynaud. Clasificación



Primario



Secundario

Capilaroscopia

Fenómeno de Raynaud 1º. Criterios



- Crisis de vasospasmo
(palidez o cianosis de partes acras)
- Pulsos periféricos presentes
- Ausencia de úlceras digitales
- Capilaroscopia normal
- AANs: negativos
- VSG: normal

LeRoy y Medsger, 1992

Capilaroscopia: fenómeno de Raynaud

Fenómeno de Raynaud 2º

Dilatación



Megacapilares



Pérdida capilar



Fenómeno de Raynaud 2º. Causas

Conectivopatías

Oclusión arterial

Endocrinopatías

Neoplasias

Anomalías hematológicas

Micotraumatismos

Alteraciones vasospásticas

Infecciones

Fármacos

Síndrome del aceite tóxico

F. Raynaud y Enfermedades del tejido conjuntivo


- Esclerodermia 95%
- EMTC 91%
- LES 10-45%
- Síndrome de Sjögren 35%
- Dermatomiositis 20-30%
- Artritis reumatoide 10-20%

Autoantibodies and Microvascular Damage Are Independent Predictive Factors for the Progression of Raynaud's Phenomenon to Systemic Sclerosis

A Twenty-Year Prospective Study of 586 Patients,
With Validation of Proposed Criteria for Early Systemic Sclerosis

Koenig M et al. *Arthritis and Rheumatism*. 2008;58:3.902-12


Last, this study is the first to validate the criteria for early SSc that were proposed by LeRoy and Medsger, but were not validated (21). According to these criteria, when the presence of RP is subjective only (i.e., by patient report only), as in the present study, early SSc may be diagnosed when both an SSc pattern on NCM and SSc-specific autoantibodies are observed (21). In our cohort, patients in whom both predictors were present at baseline were 60 times more likely to develop definite SSc than were patients without these predictors.




Conclusion. In RP evolving to definite SSc, microvascular damage is dynamic and sequential, while SSc-specific autoantibodies are associated with the course and type of capillary abnormalities. Abnormal findings on NCM at baseline together with an SSc-specific autoantibody indicate a very high probability of developing definite SSc, whereas their absence rules out this outcome.



Pre-esclerodermia




Fenómeno de Raynaud
AANs (específicos)
Alter. Capilaroscópicas
(Edema/úlceras digitales)





Vasculitis

Capilaroscopia



E.M.T.C

Conectivopatías



Sd. de Sjögren



L.E.S.



Dermatomiositis

Morphologic capillary changes and manifestations of connective tissue diseases in patients with primary biliary cirrhosis

V Fonollosa^{1*}, CP Simeón¹, L Castells¹, F Garcia¹, A Castro¹, R Solans¹, J Lima¹, V Vargas¹, J Guardia¹ and M Vilardell¹

¹Department of Internal Medicine, Hospital General Universitari Vall d'Hebron, Universitat Autònoma Barcelona, Barcelona, Spain


Lupus (2001) **10**, 628–631.

Table 1 Nailfold capillary findings in the PBC and control groups

	<i>PBC group</i>	<i>Control group</i>
Patients	22	15
Capillary loop dilatation	3	0
Haemorrhage	1	0
Tortuosities	8	2
Megacapillaries	8	0
Normal	2	13



Nailfold Capillary Microscopy in Adults with Inflammatory Myopathy



* $P < 0.05$

*Selva A, Fonollosa V, Trallero E et al.
Semin Arthritis Rheum 2010;39:398-404*

Capilaroscopia




Dilataciones



Desestructuración
vascular



Megacapilares



Pérdida capilar



Megacapilares

Esclerodermia




Hemorragias

CAPILAROSCOPIA. Esclerodermia

Patrones capilaroscópicos*

Patrón activo

pérdida capilar intensa
desestructuración vascular
dilataciones escasas



Patrón lento

dilataciones-megacapilares
pérdida discreta



*HR.Mariqc

CAPILAROSCOPIA. PATRONES: “Early” – “Active” – “Late”

Cutolo M et al. *J Rheumatol* 2000;27:155-60




Figure 3. Normal capillary patterns (top left), and patterns seen in scleroderma. Early (top right): few giant capillaries (G), and microhemorrhages (H). Active (bottom left): increased number of giant capillaries and microhemorrhages, together with loss of capillaries (L). Late (bottom right): dramatic loss of capillaries, neoangiogenesis (N), and fibrosis (F).




Figure 2. Specific microvascular changes that characterize the different nailfold videocapillaroscopic systemic sclerosis patterns. Top left, Normal capillary array. Top right, Early pattern. Bottom left, Active pattern. Bottom right, Late pattern. M = microhemorrhages; G = giant capillaries; L = loss of capillaries; N = neoangiogenesis (original magnification $\times 220$).

ARTHRITIS & RHEUMATISM
Vol. 62, No. 9, September 2010, pp 2595–2604
DOI 10.1002/art.27543
© 2010, American College of Rheumatology

REVIEW

Clinical Implications From Capillaroscopic Analysis in Patients With Raynaud's Phenomenon and Systemic Sclerosis

Ariane L. Herrick¹ and Maurizio Cutolo²

patterns. However, it must be recognized that these capillaroscopic patterns are descriptive, that there is inevitable overlap between patterns, and that further studies are indicated to examine changes in patterns over time.


CAPILAROSCOPIA. Esclerodermia

PATRÓN ACTIVO

Forma difusa
Crisis renal esclerodérmica
Úlceras digitales
Anti-topoisomerasa I
Peor pronóstico
Criterios de la ARA

PATRÓN LENTO


Forma limitada
Anticentrómero




PATRONES / SUBTIPOS

Capilaroscopia y Esclerodermia


N: 319 pacientes- N: 235capilaroscopias



SERIE GLOBAL



SUBTIPO DIFUSA



SUBTIPO LIMITADA/SINE

P= 0,02

Global	P.Activo	P Lento
5 años	82,8%	99,5%
15 años	76,9%	92,5%
25 años	58,8%	83%

P=0,005

DIFUSA	Activo	Lento
5 años	72,2%	95,7%
15 años	65,6%	95,7%
25 años	35%	77,3%

LIMIT/SINE	Activo	Lento
5 años	94,7%	99,4%
15 años	89,2%	92,2%
25 años	82,3%	83,6%


ESCLERODERMIA. Clasificación en subtipos

Pre-esclerodermia

Fenómeno de Raynaud
Sin afección cutánea
Úlceras digitales
Alts. capilaroscópicas
AAN específicos

Forma difusa

F. de Raynaud <1a.
Afección troncal y acra
Roces tendinosos
Afección visceral temprana
Pérdida capilar
Anti-Scl 70 (25-30%)



Forma limitada

F. de Raynaud >5a.
Afección cutánea distal
Telangiectasias, calcinosis
afección digestiva. HTAP
Dilatación capilar
AAcentrómero (59-80%)

ESC sine esclerodermia

F. de Raynaud +/-
Sin afección cutánea
Afección visceral
AAN específicos

2013 Classification Criteria for Systemic Sclerosis

An American College of Rheumatology/European League
Against Rheumatism Collaborative Initiative

Van den Hoogen F et al. Arthritis Rheum. 2013

Table 1. The American College of Rheumatology/European League Against Rheumatism criteria for the classification of systemic sclerosis (SSc)*

Item	Sub-item(s)	Weight/score†
Skin thickening of the fingers of both hands extending proximal to the metacarpophalangeal joints (<i>sufficient criterion</i>)	–	9
Skin thickening of the fingers (<i>only count the higher score</i>)	Puffy fingers	2
	Sclerodactyly of the fingers (distal to the metacarpophalangeal joints but proximal to the proximal interphalangeal joints)	4
Fingertip lesions (<i>only count the higher score</i>)	Digital tip ulcers	2
	Fingertip pitting scars	3
Telangiectasia	–	2
Abnormal nailfold capillaries	–	2
Pulmonary arterial hypertension and/or interstitial lung disease (<i>maximum score is 2</i>)	Pulmonary arterial hypertension	2
	Interstitial lung disease	2
Raynaud's phenomenon	–	3
SSc-related autoantibodies (anticentromere, anti-topoisomerase I [anti-Scl-70], anti-RNA polymerase III) (<i>maximum score is 3</i>)	Anticentromere	3
	Anti-topoisomerase I	
	Anti-RNA polymerase III	

CAPILAROSCOPIA. Aplicación clínica



Fenómeno de Raynaud 1º-2º

Esclerodermia:

ESC. Inicial

Criterios de clasificación

Pronóstico



Dermatomiositis

EMTC

Reunión del grupo de trabajo para el estudio de la capilaroscopia. GEAS. Línea esclerodermia. Madrid. Febrero 2013



- Análisis cualitativo
- Análisis cuantitativo
- Patrones capilaroscópicos
- Base de datos
- Informe
- Planificación

Reunión del grupo de trabajo para el estudio de la capilaroscopia. GEAS. Línea esclerodermia. Madrid. Febrero 2013



Dra. Ana Bielsa
Dra. M^a Jesús Castillo
Dr. Gerard Espinosa
Dra. Patricia Fanlo
Dr. Vicent Fonollosa
Dra. Mayka Freire
Dra. Begoña Marí
Dr. Norberto Ortego
Dr. Juan José Ríos
Dr. Luis Sáez
Dr. Albert Selva
Dr. José Todolí



APP STORE: capilaroscopia
www.capilaroscopia.es



Con la colaboración de:  **ACTELION**